Media stories about Fate Therapeutics (NASDAQ:FATE) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fate Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.3534910066436 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
NASDAQ FATE opened at $11.54 on Wednesday. The stock has a market cap of $608.99, a PE ratio of -11.31 and a beta of 1.74. The company has a current ratio of 9.29, a quick ratio of 9.29 and a debt-to-equity ratio of 0.19. Fate Therapeutics has a one year low of $2.52 and a one year high of $14.45.
Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.05). The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.02 million. Fate Therapeutics had a negative return on equity of 71.00% and a negative net margin of 1,046.08%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. research analysts anticipate that Fate Therapeutics will post -0.94 earnings per share for the current fiscal year.
A number of research firms have recently commented on FATE. BMO Capital Markets raised their price target on Fate Therapeutics from $7.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 6th. Wells Fargo reaffirmed an “outperform” rating and set a $19.00 price target (up previously from $10.00) on shares of Fate Therapeutics in a research report on Tuesday, March 6th. HC Wainwright lowered Fate Therapeutics from a “buy” rating to a “neutral” rating and set a $12.00 price target on the stock. in a research report on Tuesday, March 6th. UBS lowered Fate Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $10.00 price target (down previously from $19.00) on shares of Fate Therapeutics in a research report on Tuesday, March 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Fate Therapeutics has an average rating of “Buy” and a consensus target price of $15.00.
COPYRIGHT VIOLATION WARNING: “Fate Therapeutics (FATE) Receives Coverage Optimism Score of 0.17” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/18/fate-therapeutics-fate-receives-coverage-optimism-score-of-0-17.html.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.